Skip to main content
. 2009 Sep 15;58(12):2863–2872. doi: 10.2337/db09-0158

FIG. 5.

FIG. 5.

Effects of EPO on phosphorylation of Akt and GSK-3β at reperfusion. A: Akt. B: GSK-3β. □, Control (i.e., 20-min ischemia/5-min reperfusion); ▨, EPO (5,000 units/kg i.v., plus 20-min ischemia/5-min reperfusion). *P < 0.05 vs. control. n = 4–7. C: Effects of PD98059 on EPO-induced phosphorylation of GSK-3β at reperfusion in OLETF rats treated with TUDCA (O+TUD). *P < 0.05 vs. EPO. n = 3. D: Relationship between increases in phospho–GSK-3β levels by EPO from control and mean infarct size reduction by EPO in each treatment group. See data of infarct size experiments (Fig. 1) and immunoblot experiments (Fig. 5B and C). ○, LETO; ●, OLETF; △, OLETF+TUDCA; ▲, EPO+PD98059 treatment in OLETF and TUDCA rats.